All In MedTech

Device Trial Radar · NCT06037109

VIDAS® NEPHROCLEAR Reference Interval Study

VIDAS® NEPHROCLEAR CCL14 Reference Interval Study

Last checked: Nov 21, 2026Latest source record: Feb 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

585

Actual

Start

Jul 18, 2023

Primary completion

Dec 28, 2023

Study completion Dec 28, 2023

Sponsor

Lead sponsor
BioMérieuxNot on our public-company list
Sponsor type
Industry
First posted
Sep 14, 2023

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 21 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a multi-center sample analysis study in which urine samples previously collected from apparently healthy adult subjects, and subjects with stable chronic morbidities but without AKI in order to establish the reference range for the VIDAS® NEPHROCLEAR™ CCL14 test.

Conditions

  • Healthy

Interventions

  • Diagnostic Test: VIDAS® NEPHROCLEAR™ CCL14 TestDevice

    Previously collected urine samples will be tested using the VIDAS® NEPHROCLEAR™ CCL14 Test

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CCL14 concentration in urineTime frame: Samples tested within 2 years of collection

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • George Washington University

    Washington D.C., District of Columbia

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.